| Literature DB >> 33330807 |
Wataru Matsuda1, Tatsuya Okamoto2, Tatsuki Uemura1, Kentaro Kobayashi1, Ryo Sasaki1, Akio Kimura1.
Abstract
Severe COVID-19 is associated with a hyperinflammatory state, and corticosteroid therapy may be effective. We review the recent literature and discuss the appropriate dose and duration of corticosteroid therapy. Low-dose corticosteroid therapy is often used to treat COVID-19. However, several doses of methylprednisolone (or prednisolone) have been attempted, ranging from about 40 mg/day to 2 mg/kg/day. Doses may need to be adjusted depending on severity. Corticosteroid therapy is generally administered for a short period over several days. However, COVID-19-induced respiratory failure is often prolonged, so longer administration may be considered. Careful monitoring for complications due to corticosteroid therapy is vital. 2020, National Center for Global Health and Medicine.Entities:
Keywords: COVID-19; SARS-CoV-2; acute respiratory distress syndrome; complications; corticosteroid therapy; viral RNA clearance
Year: 2020 PMID: 33330807 PMCID: PMC7731176 DOI: 10.35772/ghm.2020.01046
Source DB: PubMed Journal: Glob Health Med ISSN: 2434-9186